Anti-Diabetes Drugs - Indonesia | Statista Market Forecast

In Indonesia, the revenue in the Anti-Diabetes Drugs market is forecasted to reach US$418.80m by 2024.
Looking ahead, the market is expected to exhibit a compound annual growth rate (CAGR) of 7.83% from 2024 to 2029, resulting in a market volume of US$610.70m by 2029.
It is worth noting that, compared to other countries, United States is projected to generate the highest revenue in the Anti-Diabetes Drugs market, with an estimated value of US$37.84bn in 2024.
In recent years, Indonesia has seen an increasing demand for locally-produced anti-diabetes drugs, as the government focuses on promoting domestic pharmaceutical industry.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Indonesia has been experiencing steady growth in recent years.

Customer preferences: As the population of Indonesia continues to age and become more urbanized, the number of people with diabetes is increasing. This has led to a growing demand for anti-diabetes drugs in the country. Additionally, there has been a shift in consumer preferences towards more convenient and effective treatment options.

Trends in the market: One of the key trends in the Anti-Diabetes Drugs market in Indonesia is the increasing popularity of combination therapies. These drugs combine multiple active ingredients to provide a more comprehensive treatment approach. Another trend is the growing adoption of injectable drugs, which offer more precise dosing and better blood sugar control.

Local special circumstances: Indonesia has a large population and a growing middle class, which is driving demand for healthcare services. However, the country also faces challenges in terms of healthcare infrastructure and access to care, particularly in rural areas. This has led to a focus on improving healthcare delivery and expanding access to treatment for chronic diseases like diabetes.

Underlying macroeconomic factors: The Indonesian economy has been growing steadily in recent years, which has helped to support the growth of the Anti-Diabetes Drugs market. However, the country also faces challenges such as inflation and currency fluctuations, which can impact the affordability of healthcare services and drugs. Additionally, the government has been implementing healthcare reforms aimed at improving access to care and reducing costs, which could have an impact on the Anti-Diabetes Drugs market in the future.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.